Clinical Trials Logo

ICC clinical trials

View clinical trials related to ICC.

Filter by:
  • None
  • Page 1

NCT ID: NCT06447454 Not yet recruiting - ICC Clinical Trials

Combining Chemoradiotherapy With Sintilimab in First-Line ICC

Start date: July 1, 2024
Phase:
Study type: Observational

To evaluate the effectiveness and safety of GC (gemcitabine + cisplatin) and radiotherapy combined with slulimumab in the treatment of first-line intrahepatic cholangiocarcinoma patients

NCT ID: NCT04769908 Recruiting - ICC Clinical Trials

Systemic Chemotherapy, Lenvatinib Plus Sintilimab for ICC With Distant Metastasis

Start date: February 23, 2021
Phase: Phase 2
Study type: Interventional

This study were designed to verify the better method of survival for ICC with distant metastasis. Since the traditional method for ICC with distant metastasis. was GEMOX(first-line treatment from NCCN guideline), our previous study found similar results from FOLFOX (second-line treatment from NCCN guideline) compared with GEMOX. Our current study were conducted for further investigation to verify the better method for with distant metastasis.

NCT ID: NCT04682249 Withdrawn - ICC Clinical Trials

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Start date: December 1, 2020
Phase: Phase 2
Study type: Interventional

This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(first-line treatment from NCCN guideline), our previous study found similar results from FOLFOX (second-line treatment from NCCN guideline) compared with GEMOX. Our current study were conducted for further investigation to verify the better method for metastatic ICC.

NCT ID: NCT04398927 Withdrawn - Metastatic Cancer Clinical Trials

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

This study were designed to verify the better method of survival for metastatic ICC. Since the traditional method for metastatic ICC was GEMOX(recommended from NCCN guideline), our previous study found better results from Folfirinox over GEMOX. Our current study were conducted for further investigation to verify the better method for metastatic ICC.

NCT ID: NCT03940378 Recruiting - ICC Clinical Trials

Treatment of Advanced Intrahepatic Cholangiocarcinoma

TAICC
Start date: February 1, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of Levamisole Hcl in the treatment of patients with advanced intrahepatic cholangiocarcinoma.